Star Combo Pharma Ltd and the University of Technology Sydney (UTS) have fortified their co-operation by officially executing a Memorandum of Understanding (MOU) to promote cooperative scientific research and innovation.
Group photo after signing the Memorandum of Understanding (MOU) to promote cooperative scientific research and innovation between the University of Science and Technology (UTS) and Star Combo Pharma Ltd. (L to R) Professor Charlie Benrimoj (Head, Graduate School of Health, University of Technology Sydney); Professor Williams, Kylie (Head of Discipline (Pharmacy), University of Technology Sydney); Su Zhang (CEO, Star Combo Pharma Ltd); Dr Kamal Dua (Lecturer, Discipline of Pharmacy, University of Technology Sydney).
The MOU was officialised by Professor Charles Rice, Deputy Vice-Chancellor and Vice-President (Research) on behalf of the University of Technology Sydney (UTS), and Ms Su Zhang, Director and CEO of Star Combo Pharma Ltd on 16th February, 2018.
The cooperation was signalled by a strong start with Professor Kylie Williams, PhD, Head of Discipline (Pharmacy), UTS, officially introducing Ms Su Zhang as UTS’ pharmaceutical industry partner to the students, and Ms Su Zhang giving a guest lecture to graduate students of Graduate School of Health, UTS.
University of Technology, Sydney (UTS) is located in the heart of Sydney, the capital of New South Wales, Australia. It is a comprehensive research university with strong disciplines of business, law, education and science and technology.
Known as one of the most respected young universities in Australia, UTS is a success with its unique learning model, strong research and cooperation with industry professionals and its good reputation. UTS is ranked among the top 200 universities according to the latest QS World University Rankings 2018, and is ranked first in Australia in rankings for the world’s young university (less than 50 years of school age).